PerkinElmer (PKI) agrees to buy Caliper Life Sciences (CALP) for $10.50 a share, a 42% premium over yesterday's closing price. The $600M deal adds "innovative molecular imaging and detection technologies" to PerkinElmer's portfolio, according to its CEO. Shares of CALP +40% premarket.
With the 2011 Advances in Genome Biology and Technology conference getting underway tomorrow, life sciences companies may get a little extra attention. Major presenters/participants include Illumina (ILMN), Life Technologies (LIFE), Caliper Life Sciences (CALP), Agilent (A), Pacific Biosciences (PACB), and Complete Genomics (GNOM).